Rapport Therapeutics Inc. charted a path for its initial public offering and executed the IPO according to the plan it laid out for investors, reaping a slight reward on its first day of trading on 7 June during a period when other newly public biopharmaceutical companies have struggled to keep their heads above water.
Key Takeaways
-
Rapport raised $154m with a $136m IPO and concurrent $18m private placement and its stock performed well in its first day of trading.
Boston- and San Diego-based Rapport priced its offering of 8 million shares at $17 each on 6 June, right in...